Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Jeffrey C. Thompson[a,*], Ryan Fan[b], Taylor Black[b], Gordon H. Yu[c], Samantha L. Savitch[b], Austin Chien[b], Stephanie S. Yee[b], Moen Sen[b], Wei-Ting Hwang[d,f], Sharyn I. Katz[e,f], Michael Feldman[c,f], Anil Vachani[a,f], Erica L. Carpenter[b,f]

[a] *Division of Pulmonary, Allergy and Critical Care Medicine, Thoracic Oncology Group, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States*
[b] *Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States*
[c] *Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine Philadelphia, PA, United States*
[d] *Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States*
[e] *Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States*
[f] *Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States*

A R T I C L E   I N F O

A B S T R A C T

Objectives: A malignant pleural effusion (MPE) is a common complication in non-small cell lung cancer (NSCLC) with important staging and prognostic information. Patients with MPEs are often candidates for advanced therapies, however, the current gold standard, cytological analysis of pleural fluid samples, has limited sensitivity. We aimed to demonstrate the feasibility of non-invasive enumeration and immunophenotyping of EpCAM-positive cells in pleural fluid samples for the diagnosis of a MPE in NSCLC patients.
Materials and methods: Pleural fluid specimens were prospectively collected from patients with NSCLC and the CellSearch® technology was utilized for the enumeration of pleural EpCAM-positive cells (PECs) and determination of PD-L1 expression on PECs from pleural fluid samples. The diagnostic performance of the enumeration of single PECs and PEC clusters was assessed using receiver operating characteristic (ROC) curves. The Kaplan-Meier method and Cox proportional hazards model was used to assess the impact of PECs and PEC clusters on overall survival (OS).
Results: 101 NSCLC patients were enrolled. The median number of PECs was significantly greater in the malignant (n = 84) versus non-malignant group (n = 17) (730 PECs/mL vs 1.0 PEC/mL, p < 0.001). The area under the ROC curve was 0.91. A cutoff value of 105 PECs/mL had a sensitivity and specificity of 73% and 100% for the diagnosis of a MPE, respectively. Among 69 patients with a pathology-confirmed MPE and tissue immunohistochemistry (IHC) results, 15 (22%) had greater than 50% PD-L1 + PECs. Overall concordance between tissue and PEC PD-L1 expression was 76%. Higher numbers of pleural effusion single PECs were associated with inferior overall survival (Cox adjusted HR 1.8, 95% CI: 1.02–3.05 p = 0.043).
Conclusion: Non-invasive measurement of PECs in NSCLC patients, using an automated, clinically available approach, may improve the diagnostic accuracy of a MPE, allow for immunophenotyping of PECs, and provide prognostic information.

1. Introduction

Despite significant advances in detection and therapy, lung cancer remains the leading cause of cancer-related death in both men and women worldwide. Non-small cell lung cancer (NSCLC) is the most common histotype representing 85% of new diagnoses [1]. Malignant

pleural effusions (MPEs) occur as a frequent complication of advanced stage lung cancer, occurring in approximately 30% of patients, and denoting a poor overall prognosis [2,3]. NSCLC patients with a MPE have a median overall survival of only 4.3 months and are often candidates for advanced therapies [4]. Sampling of a pleural effusion in a lung cancer patient by thoracentesis is mandatory to provide accurate

---

diagnostic and staging information. However, cytological analysis remains the gold standard for the diagnosis of a MPE despite a mean sensitivity of ~60% (range 46–89%) [5–,1,2,3,4,5,6,7,8]. The detection of tumor cells in serous effusions by cytology is often limited by the scarcity of tumor cells and difficulty in distinguishing tumor cells from reactive mesothelial cells or inflammatory cells [9]. Several markers have been evaluated to distinguish malignant from benign effusions [10–,1,2,3,4,5,6,7,8,9,10,11,12], however, these have limited clinical utility.

CellSearch® is a circulating tumor cell (CTC) enrichment platform that isolates cells based on cell surface Epithelial Cell Adhesion Molecule (EpCAM) expression using an EpCAM directed capture antibody. The CellSearch® platform is currently FDA-approved for the identification and enumeration of CTCs from the peripheral blood in a variety of malignancies [13–19]. The enumeration of CTCs and multicellular aggregates of CTCs, termed CTC clusters, from blood has been associated with a poor overall prognosis [16,19–22]. In addition, CTC clusters have significantly increased metastatic potential when compared to individual CTCs [23–26]. While CellSearch® has primarily been employed as an assay to detect single CTCs in peripheral blood, this approach has had very low sensitivity for NSCLC [13,27]. To address this, we have previously demonstrated the ability to adapt this technology to detect PECs from MPEs in patients with epithelial malignancies [28]. The ability to detect rare PECs from pleural effusions (analogous to CTCs detected in blood) in patients with NSCLC could improve the diagnostic accuracy of conventional cytological analysis and provide improved prognostic information. In addition, the CellSearch® system allows one to further characterize tumor cells with user-defined markers of interest, by adding a fluorochrome-conjugated antibody to the open channel. This approach has previously been used to study cell surface markers on CTCs isolated from the peripheral blood, including IGF1R, HER2, EGFR, and PD-L1 [29–33]. To our knowledge, this non-invasive approach for immunophenotyping has not previously been demonstrated for PECs from MPEs. The assessment of pleural fluid samples using CellSearch® could represent a novel approach to enrich tumor cells often undetectable in the blood of NSCLC patients [13] and further phenotype these cells for markers of interest that could not otherwise be detected in circulating tumor DNA.

The expression of the programmed death-ligand 1 (PD-L1) on the surface of tumor cells has emerged as a promising biomarker for the selection of NSCLC patients to receive immune targeted agents. Several studies have shown improved response rates to immunotherapy in NSCLC patients with high levels of PD-L1 expression. [34,35] Moreover, additional immune checkpoints, including TIM-3 and LAG-3 have been identified as being up-regulated in tumors at the time of progression on PD-1-targeted therapy [36]. Inhibitors targeting these checkpoints are currently in clinical trial. To address this ongoing need for development of non-invasive immunophenotyping approaches, we aimed to demonstrate the feasibility of using the CellSearch® CTC enrichment platform for the non-invasive enumeration and immunophenotyping of PECs in pleural fluid from NSCLC patients.

2. Materials and methods

2.1. Patients

This was a single-center, prospective, observational study conducted at the Hospital of the University of Pennsylvania from February 2016 to June 2017. Enrolled subjects had a history of NSCLC and underwent sampling of a pleural effusion at our institution. Patients with less than 200 mL of pleural fluid obtained from a diagnostic thoracentesis were excluded from the study to ensure sufficient volume of fluid for routine clinical tests. A total of 101 subjects were included in the study. Baseline demographics and clinical variables, such as tissue mutation status, pathology results, treatment regimens and outcome data were obtained from periodic chart review of the electronic medical record

Table 1
Patient characteristics.

	All Patients (n = 101)	
	Number	%
Median age (range)	66 (37–91)	–
Sex		
Male	46	46
Female	55	54
Race		
Asian	11	11
Black	14	14
White	73	72
Other	3	3
Smoking status[a]		
Never smoker	33	33
Former smoker	60	59
Current smoker	7	7
ECOG status		
0-1	78	77
2	18	18
3	5	5
Stage		
I	8	8
II	4	4
III	13	13
IV	76	75
Histology		
Adenocarcinoma	82	81
Squamous cell carcinoma	11	11
Poorly differentiated carcinoma	8	8
Therapeutic regimen at time of effusion		
Chemotherapy	23	23
Tyrosine Kinase Inhibitor	14	14
Immunotherapy	12	12
None	52	51

[a] Smoking status unknown for 1 patient.

(patient characteristics in Table 1). Study data were collected and managed using the REDCap electronic data capture tools hosted at the University of Pennsylvania. [37] A malignant pleural effusion was defined as having at least one of the following features 1) positive cytological analysis 2) positive pleural biopsy or 3) determined to be malignant by the treating physician based on clinical characteristics. Clinical characteristics to determine a MPE in the absence of pathologic confirmation included evidence of tumor involvement of the pleural surface by cross-sectional imaging or patients with metastatic NSCLC with no alterative explanation for a pleural effusion. An effusion that had a definitive benign etiology or did not meet criteria for a MPE was defined as a non-malignant effusion. Mutations in the *EGFR* gene that confer sensitivity to an EGFR-targeted therapy were defined as targetable *EGFR* mutations. Specific *EGFR* mutations detected in our cohort included: Exon 19 deletions, L858R, L861 K, G719S, and E709 A. This study was approved by the University of Pennsylvania Institutional Review Board.

2.2. Pleural effusion sample collection and preparation

10 mL of unprocessed pleural fluid was collected in a CellSave preservative tube (Menarini Silicon Biosystems) following thoracentesis. Samples were maintained at ambient temperature and 1 mL of pleural fluid was processed within 96 h of collection in accordance with manufacturer guidelines.

2.3. Enumeration of PECs and PEC clusters from pleural effusions

CTC enumeration from blood using the CellSearch® technology has been previously described [13]. We adapted the CellSearch® AutoPrep (Menarini Silicon Biosystems) platform to isolate pleural EpCAM-

positive cells (PECs) present in the pleural fluid of NSCLC patients for our study. Briefly, the CellSearch® CXC kit (Menarini Silicon Biosystems) utilizes a ferromagnetic particle reagent solution incubated with anti-EpCAM antibodies to capture and enrich EpCAM + cells present in the pleural fluid. Enriched cells were stained with the following fluorescent antibodies: anti-cytokeratin (CK) to identify epithelial cells, anti-CD45-Allophycocyanin (APC) to identify white blood cells, and 4′,6-diamidino-2-phenylindole (DAPI) to identify nucleated cells. Identification, enumeration, and marker expression of PECs were performed using the CellTracks Analyzer II (Menarini Silicon Biosystems), a semi-automated fluorescent microscope system. $EpCAM^+/CK^+/CD45^-/DAPI^+$ cells were enumerated and counted as individual PECs. Results are expressed as the number of PECs/mL of pleural fluid. A PEC cluster was defined as two or more $EpCAM^+/CK^+/CD45^-/DAPI^+$ cells with surface membrane contact within a single image frame on the Cell-Tracks Analyzer II (representative images shown in Supplemental Fig. 1). PEC clusters were enumerated and results expressed as the number of PEC Clusters/mL of pleural fluid.

2.4. PEC PD-L1 expression validation and evaluation

The anti-human CD274 (PD-L1) antibody (BioLegend) was added to the open 4th channel of the CellSearch® AutoPrep allowing for marker staining during sample processing. To validate PEC PD-L1 expression using the anti-human CD274 (PD-L1) antibody, peripheral blood spiking experiments with PD-L1 positive (PD-L1 transfected EM-Meso) and PD-L1 negative (BT-474) control cell lines were conducted using normal donor blood and analyzed using the CellSearch® platform with results compared to flow cytometry analysis (Supplemental Fig. 2). The percentage of PD-L1 positive PECs was determined by dividing the number of PD-L1+ PECs by the total number of PECs detected in the pleural effusion sample. Patients with a cytologically positive MPE had the pleural effusion cellblock stained for PD-L1 expression using the E1J2J PD-L1 antibody (Cell Signaling Technology). This was the standard antibody for PD-L1 testing of formalin-fixed paraffin-embedded tissue during the study period and binds the same PD-L1 domain as the anti-human CD274 (PD-L1) antibody (Biolegend). Human tonsillar tissue was used as a positive staining control. Each slide was reviewed by an independent cytopathologist and scored for membranous PD-L1 staining on the tumor cells present in less than or greater than 50% of the cells. 50 of the 69 patients with a pathologically confirmed MPE had sufficient cytological tissue for IHC analysis.

2.5. Statistical analysis

Descriptive statistics such as mean, median, and proportions were used to summarize patient demographics and tumor characteristics. Non-parametric Wilcoxon rank-sum test was utilized to compare the number of PECs and PEC clusters between malignant and non-malignant MPEs. The performance of the number of PECs and PEC clusters for distinguishing malignant and non-malignant MPEs was assessed using receiver operating characteristic (ROC) curves and the area under the curve (AUC). Optimal cutoff points were selected as the point on the ROC curve with the minimum distance from the upper-left corner of the unit graph. Sensitivity and specificity and the associated 95% confidence intervals (CI) were computed. Among 50 patients with a pathologically confirmed MPE and sufficient cytological tissue for IHC analysis, PD-L1 expression between tissue and PECs was considered concordant if both PD-L1 expressions were above or below a threshold value of 50%. To determine whether the number of PECs and PEC Clusters were associated with overall survival (OS), Kaplan-Meier curves were plotted according to high and low PECs and PEC Clusters and compared by a log-rank test. High and low groups were defined by whether the number of PECs and PEC clusters were above or below the median values detected in the clinically confirmed MPEs. To control for possible confounding effects, a multivariable Cox proportional hazards

model was fitted while adjusting for age, sex, smoking history (yes/no), ECOG status (≥ 2), and EGFR mutation status (mutated/not-mutated). Stata v. 14 (StataCorp) was used for all analyses, and a two-sided p-value of < 0.05 was considered statistically significant.

3. Results

3.1. Patient characteristics

Pleural fluid specimens were collected from 101 NSCLC patients at the Hospital of the University of Pennsylvania between February 2016 and June 2017 (see Table 1 for patient characteristics). The majority of patients, 76 (75%), had stage IV disease at the time of enrollment. A MPE was present at the initial diagnosis of NSCLC in 27 patients (27%), and the confirmation of a MPE resulted in the diagnosis of stage IV disease in an additional 10 patients previously diagnosed with stage I-III NSCLC. Adenocarcinoma was the most common histology (81%), with only 11% of subjects having squamous cell carcinoma (SqCC). The lower incidence of SqCC in this study compared to the general population (20–50%) [38] may be attributable to the fact that one-third of the patients were never smokers. Approximately half of the patients (49%) were receiving systemic therapy at the time of their pleural fluid sampling. 86 patients had evaluable tissue sequencing results for clinically relevant mutations in *EGFR, EML4-ALK,* and *KRAS*. A targetable *EGFR* mutation was found in 20 patients (20%), 5 patients (5%) had an *EML4-ALK* fusion, and 17 patients (17%) were identified to have a *KRAS* variant. The increased frequency of *EGFR* mutations in NSCLC patients with a MPE compared to the general NSCLC population in the US (~10–14%) [39,40] is consistent with previous reports [41–44].

3.2. PEC enumeration in malignant vs. non-malignant MPE

A malignant or non-malignant etiology for the pleural effusion was first established by cytology prior to or concurrently with pleural fluid PEC enumeration. We used the CellSearch® CTC enumeration platform to quantify the number of PECs present per mL of pleural fluid, and PEC counts were compared between the malignant and non-malignant cohorts. Initial cytological examination determined that 57 patients (56%) had a MPE, while 44 patients (44%) were determined to have a non-malignant effusion. The median number of PECs in the cytology positive and cytology negative groups was 2121 PECs/mL (range:0-114,920 PECs/mL) and 12.5 PECs/mL (range:0-11,007 PECs/ml) (p < 0.001, Fig. 1A), respectively. In the cytology negative group, 36 (82%) patients underwent repeat pleural fluid sampling or pleural biopsy to further evaluate the etiology of the effusion, and 12 of these patients were ultimately diagnosed with a pathologically confirmed MPE. The median number of PECs detected in subjects with a pathologically confirmed MPE was significantly higher than the pathology negative group (1616 PECs/mL vs 6.5 PECs/mL, p < 0.001) (Fig. 1B). An additional 15 patients were determined to have a MPE based on clinical characteristics but were not pathologically confirmed. In total, 84 patients were determined by cytology, pathology, or clinical characteristics to have a MPE, with 17 patients identified to have a benign effusion after clinical review. The median number of PECs detected in subjects with a MPE after clinical review was significantly higher than the non-malignant group (730 PECs/mL vs 1.0 PEC/mL, p < 0.001) (Fig. 1C). There was no significant difference in the number of PECs detected in pleural effusions between the 49 patients receiving therapy at the time of effusion sampling and the 52 not receiving therapy (p = 0.442; data not shown). The performance of PEC enumeration for the diagnosis of a MPE was assessed using ROC curves. The area under the ROC curve was 0.91 (95% CI: 0.86-0.97) demonstrating excellent discriminatory ability (Fig. 1D). The optimal cutoff point of 105 PECs/mL was selected and had a sensitivity of 73% and specificity of 100% for the diagnosis of a MPE in NSCLC (Supplemental Table 1). Using this threshold value of 105 PECs/mL to diagnose a MPE would have

Fig. 1. Pleural effusion PEC counts as determined by first cytological analysis, any pathological review, or clinical characteristics. (A) PEC counts per mL of fluid in the cytology negative and cytology positive groups as determined by first cytological analysis (n = 101, p < 0.001). The median number of PECs/mL was significantly higher in the cytology positive compared to the cytology negative groups (2121 vs 12.5, p < 0.001) (B) PEC counts per mL after any pathological review of pleural effusion. The median number of PECs/mL was significantly higher in the pathologically confirmed MPEs compared to the pathology negative groups (1616 vs 6.5, p < 0.001). Data points marked in red denote the 12 cytology negative patients who were ultimately determined to have a malignant phenotype after pathological review. (C) PEC counts per mL after any clinical review of pleural effusion. The median number of PECs/mL was significantly higher in the malignant compared to the non-malignant groups (730 vs 1, p < 0.001). Data points marked in red denote 27 patients with an initial cytologically negative effusion who were ultimately determined to have a malignant phenotype after pathology or clinical review (D) Receiver Operator Characteristics curve (ROC curve) for PECs in pleural fluid does discriminate between benign and malignant effusions: cutoff 105 PECs/mL sensitivity 73%, specificity 100%, AUC 0.91(95% CI: 0.86-0.97). Solid horizontal lines indicate median values in panels A–C. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Fig. 2. Patient 067 diagnosed with stage IIA NSCLC based on negative cytology from thoracentesis. (A) Baseline PET/CT showing a PET avid right lower lobe mass abutting the pleura and a moderate size pleural effusion. (B) Imaging 12 months after initial diagnosis showing metastatic pleural implants (*) and pleural nodularity. (C) Timeline depicts patient history over 14 months. The initial effusion had 853 PECs/mL. Patient was treated with localized radiation with curative intent. Despite treatment, patient had a progressive decline in her functional status and was ultimately transitioned to hospice 14 months after diagnosis. Results of PEC enumeration suggest this patient likely had a malignant pleural effusion at diagnosis despite negative cytology results.

reclassified 11 (11%) patients with an initial cytologically negative effusion that were ultimately identified as a MPE (Fig. 1C). Three of the 11 patients required a thoracoscopic pleural biopsy to diagnose a MPE.

### 3.3. Clinical Utility of PEC enumeration for the diagnosis of MPE in NSCLC

Among the 32 patients without pathologic evidence of a MPE (Fig. 1B), patient 067 appeared to be an outlier with a PEC count of 853 PECs/mL, well above the median of 6.5 and the next highest patient with 102 PECs/mL. This patient was a 73-year-old female found to have a 5 cm right lower lobe mass with a moderately sized right pleural effusion (Fig. 2). A biopsy of the right lower lobe mass confirmed NSCLC, squamous histology. Pleural fluid sampling at the time of diagnosis was negative for malignancy by cytological analysis. PEC enumeration of the initial pleural fluid sample revealed 853 PECs/mL. Based on cytology, the patient was diagnosed with stage IIA NSCLC and treated with definitive radiation therapy. Her pleural effusion persisted and she underwent repeat pleural fluid sampling at 6 months and 11 months after initial diagnosis. Both of these pleural fluid samples were negative by cytological analysis, however, the second sample was "suspicious" for malignancy. Neither was evaluated by CellSearch®. A CT chest performed 12 months after the initial diagnosis showed new pleural tumor implants and pleural nodularity consistent with stage IV disease. This patient was ultimately diagnosed with a MPE based on clinical characteristics.

3.4. PD-L1 Expression in Malignant PECs and clusters from pleural fluid

To assess the feasibility of immunophenotyping PECs present in MPEs of NSCLC patients, the anti-human CD274 (PD-L1) antibody was added to the open 4th channel of the CellSearch® platform. For the 69 patients with a pathologically confirmed MPE (see Fig. 1B), the percentage of PECs expressing PD-L1 was calculated and compared to immunohistochemical PD-L1 staining from the corresponding pleural effusion cellblock. Patients with a pathologically confirmed MPE were evaluated so that a comparison between PEC PD-L1 expression and the corresponding tissue cellblock could be made. Representative PEC images demonstrating PD-L1 positive and negative PECs with associated IHC results are shown in Fig. 3A and B. In the 69 patients with a pathologically confirmed MPE, the median percent of PD-L1 + PECs was 6.9% (range 0–100%) (Fig. 3C). 15 patients (22%) had greater than 50% PEC PD-L1 expression. 50 patients with a pathologically confirmed MPE had sufficient cytological tissue from the pleural effusion cellblock for IHC analysis. The concordance between the percent PD-L1 expression as determined by CellSearch® and tissue IHC was 76%.

3.5. Analysis of PEC clusters

We next sought to determine the feasibility of measuring PEC clusters from pleural effusions. The number of PEC clusters was significantly higher in the MPE group (median 86 PEC Clusters/mL, range:0–63,935), when compared to the non-malignant group (median 0 PEC Clusters/mL, range:0–24) (p < 0.001) (Fig. 4A). The use of PEC

Fig. 3. Representative images of low and high PD-L1 expression as detected on PECs by CellSearch and IHC staining of pleural effusions. (A) Patient 022: CellSearch detected 11,404 PECs/mL, 1.4% of which expressed PD-L1. IHC staining determined the PD-L1 expression to be 0%. (B) Patient 017: CellSearch detected 1762 PECs/mL, 94% of which were PD-L1 positive. > 95% of cells stained PD-L1 positive by IHC. Concordance between CellSearch and IHC staining for PD-L1 expression was 76%. (C) PD-L1 expression in malignant effusions for the 69 patients confirmed malignant by pathology. The median value in the malignant group was 6.9%. Dotted horizontal line indicates that 15 out of 69 patients (22%) had 50% or more PD-L1+ PECs. Solid horizontal line indicates median value in panel.

clusters to discriminate a benign effusion from a MPE had an AUC of 0.88 (95% CI: 0.81-0.95) (Fig. 4B).

3.6. Survival analysis

Given that the diagnosis of a MPE in patients with NSCLC confers a poor prognosis with a median survival of 4–6 months [4,45], we next sought to determine the association of the presence of PECs and PEC clusters with overall survival. For the 84 patients identified to have a MPE, the median overall survival from the diagnosis of a MPE was 6.3 months (95% CI: 3.4–11.5). In the univariate analysis, there was no significant difference in overall survival (OS) in the high PEC group (range: 731-114,920 PECs/mL) vs the low PEC group (range: 0–728 PECs/mL) (Cox HR 1.4, 95% CI: 0.84–2.48, p = 0.19) (Fig. 5A). High and low PECs were defined as those patients above or below the median PEC count of 730 PECs/ml. The median OS in the high PEC group was 3.3 months (95% CI: 2.26–9.54) vs 10.3 months (95% CI: 4.92–14.98) in the low PEC group. There was also no significant difference in OS in the high PEC cluster group (range: 100–63,935 PEC Clusters/mL) vs the

low PEC cluster group (range: 0–71 PEC clusters/mL) (Cox HR 1.3, 95% CI: 0.75–2.21, p = 0.36) (Fig. 5B). We next performed a multivariate analysis including age, sex, smoking status, ECOG performance status, *EGFR* mutation status, high PECs, and high PEC clusters. Age, smoking status, and ECOG performance status were not significantly associated with OS and were removed from the final multivariate model (Supplemental Table 2). In the multivariate analysis, a higher number of PECs was associated with inferior OS (Cox adjusted HR 1.8, 95% CI: 1.02–3.05 p = 0.043) (Fig. 5C). The high PEC cluster group was not associated with inferior OS (Cox adjusted HR 1.7, 95% CI: 0.98–2.99 p = 0.057) (Fig. 5D).

4. Discussion

Here we present evidence for the enumeration and characterization of pleural EpCAM-positive cells (PECs) from pleural effusions for the management of NSCLC patients. Malignant pleural effusions occur as a common complication of advanced malignancies, with lung cancer being the leading cause of a MPE. [46] The accurate evaluation of a

Fig. 4. Pleural effusion PEC cluster counts and Receiver Operator Characteristics Curve. (A) Total PEC cluster count/mL for malignant and non-malignant patients after clinical review. The median number of PEC clusters/mL in the malignant group was significantly higher than in the non-malignant group: 86 PEC clusters/mL (range: 0–63,935) and 0 PEC clusters/mL (range: 0–24) p < 0.001. (B) Receiver Operator Characteristics curve (ROC curve) for PEC clusters in pleural fluid does discriminate between benign and malignant effusions: cutoff 28 PEC clusters/mL; sensitivity 62%, specificity 100%, AUC 0.88 (95% CI 0.81-0.95).

Fig. 5. Overall survival in patients with a MPE (n = 84) between (A) the high and low PEC groups and (B) high and low PEC cluster groups, univariate analysis. High and low groups were defined by whether the number of PECs and PEC clusters were above or below the median values detected in the clinically confirmed MPEs. Median values in each group were: PECs = 730 PECs/ml, PEC clusters = 86 PEC clusters/ml. Multivariate analysis of overall survival between (C) the high and low PEC groups and (D) high and low PEC clusters.

pleural effusion in lung cancer is critical because the presence of a MPE is diagnostic of stage IV disease, informs therapy selection, and denotes a poor overall prognosis [47]. Cytological analysis of the pleural fluid remains the gold standard to diagnose a MPE. However, the sensitivity is often limited due to the scarcity of tumor cells, inherent difficulty in distinguishing cancer cells from reactive mesothelial cells or inflammatory cells, and the experience of the cytopathologist [9]. Lung cancer patients with a pleural effusion are often subjected to repeated invasive procedures to ultimately diagnose a MPE. Several studies have evaluated various molecular markers in pleural fluid to improve the diagnostic accuracy of a MPE [10–1228], however, none of these markers are currently routinely used in clinical practice.

We have previously reported on the ability of the CellSearch® platform to detect PECs in pleural effusions. In this previous study, we identified that the number of PECs recovered from pleural fluid in patients with epithelial malignancies was significantly greater than detected in blood with 90% of NSCLC patients having greater than 100 PECs detected [28]. Here, we expand upon our previous work and demonstrate the clinical utility of the CellSearch® platform for evaluating pleural effusions of NSCLC patients. In this prospective study of 101 NSCLC patients, 84 patients were ultimately found to have a MPE. The median number of PECs detected was significantly greater in the malignant vs non-malignant group (730 PECs/mL vs 1 PEC/mL, p < 0.001). The use of PECs to diagnose a MPE showed excellent discriminatory ability with an AUC of 0.91. The low level of PECs detected in the non-malignant group is likely secondary to the presence of contaminating benign epithelial cells and reactive mesothelial cells that may coexpress epithelial markers [48,49]. A cutoff value of 105 PECs/mL had a sensitivity and specificity of 73% and 100%, respectively. Thus, a high number of PECs detected in a pleural fluid sample could alert the cytopathologist to perform further immunohistochemical

stains or suggest that the patient undergo further invasive testing to ensure adequate staging of disease. A clinician may weigh the sensitivity and specificity of different threshold values of PECs/ml to help guide management decisions in NSCLC patients with a pleural effusion (Supplemental Table 1). Given the AUC of 0.91, this technology could be deployed in a clinical lab and utilized clinically in patients with a high number of PECs/ml to make the diagnosis of a MPE more definitive in the setting of diagnostic uncertainty. The potential clinical utility of this technology is highlighted by our case example in which Patient 067 had 853 PECs/mL detected from their initial diagnostic thoracentesis. The high number of PECs detected in the pleural fluid would suggest that this patient had a MPE and stage IV disease. In addition, the high number of PECs detected in only 1 mL of pleural fluid could be particularly useful in patients with a limited volume of pleural fluid available for analysis, both for the diagnosis of a MPE and for downstream genetic profiling to determine the presence of actionable genetic alterations. The CellSearch® platform has been used to identify CTCs in the cerebral spinal fluid of NSCLC patients with leptomeningeal disease with next-generation sequencing of CTCs demonstrating high concordance (89.5%) with the primary tumor [50].

An additional advantage of our approach is the ability to non-invasively quantify biomarkers of interest such as checkpoint ligands and receptors. In our cohort, 15 of 69 patients (22%) with a pathologically confirmed MPE had greater than 50% PD-L1 + PECs. This rate of PD-L1 positivity is consistent with previous reports for NSCLC patients with greater than 50% PD-L1 expression by tissue IHC [34,51]. The concordance between tissue IHC and CellSearch® for PD-L1 expression was 76%. The open 4th channel on the CellSearch® platform could also be utilized to detect other immune checkpoint receptors expressed on the tumor cell surface such as Galectin 9 and TIGIT ligand [52]. The ability to rapidly immunophenotype the tumor cells from a MPE could assess

candidacy for an immune checkpoint inhibitor or newer combination therapies or detect the emergence of resistance to an immune targeted agent. This technology may also be applied to other epithelial malignancies that frequently cause MPEs, such as breast cancer, to identify ER and HER2 positivity. This application has already been validated in peripheral blood samples of breast cancer patients [53].

Our analysis demonstrates that higher numbers of PECs were independently associated with inferior overall survival. Similar to previous reports, the presence of an activating *EGFR* mutation was associated with improved overall survival [54–57]. Higher numbers of PECs and PEC clusters detected in peripheral circulation have been associated with worse overall survival in a variety of malignancies [16,19–22]. However, to our knowledge, this is the first study demonstrating the prognostic significance of the enumeration of PECs in MPEs. The impact on survival from higher numbers of PECs may be related to increased burden of disease, however this would need to be further validated. PEC clusters have been detected by CellSearch® and other rare cell enrichment approaches and are associated with inferior survival [21,25,58]. However, while there was a trend toward worse survival for patients with high PEC clusters (Fig. 5D) in our study, this relationship was not significant (p = 0.057). This is perhaps due to differences in PEC clusters detected within a site of metastasis such as a pleural effusion compared to circulating in blood, along with the advanced level of disease exhibited by our patients and the low overall survival.

Limitations to our study include it being a single-center study with 101 NSCLC patients; other prospective, multi-center studies would be needed to validate our results. Given that CellSearch® is already FDA-approved for enumeration of CTCs from blood, such a large-scale validation study could lead to rapid clinical deployment of a pleural effusion-based test. A second limitation is that 49% of patients were receiving systemic therapy at the time of pleural effusion sampling, and this may impact levels of PD-L1 expression and PEC enumeration in our study. A third inherent limitation is the use of EpCAM as the capture antibody to detect PECs. EpCAM expression in NSCLC may range from 82 to 94% depending on the histologic subtype. [59] Low level EpCAM expression may explain the 23 out of 84 patients with a MPE as determined by clinical review who, nevertheless, had a PEC count below the threshold of 105 PECs/ml (Fig. 1C) To address this, a future direction would be to employ combinations of capture antibodies to epithelial cell markers such as MUC1 in addition to EpCAM to improve the yield of PEC detection. [60] In addition, although EpCAM has been demonstrated to be similarly expressed in both adenocarcinoma and squamous cell carcinoma of the lung [61,62], given the limited number of patients with squamous cell lung cancer in our cohort, future studies would need to be performed to further validate our results in patients with this histology. Nevertheless, to our knowledge, this prospective study is the first of its kind to demonstrate the feasibility of using the CellSearch® CTC enrichment platform for the non-invasive enumeration and immunophenotyping of PECs in pleural fluid from NSCLC patients. The ability to identify rare tumor cells in a small volume of pleural fluid using an automated technology has the potential to be utilized as an adjunct to conventional cytological analysis to improve the diagnostic yield of a MPE. We demonstrate the feasibility of using this approach to determine PD-L1 expression on PECs from MPE, and a future application would determine whether PEC PD-L1 expression from MPE predicts response to immunotherapy. The high number of PECs detected in the MPE group with a median value of 730 PECs/mL of pleural fluid could also be used for downstream genetic profiling to detect the presence of actionable mutations, suggesting a high-throughput, automated platform for enumeration, immunophenotyping, and eventual molecular analysis of non-invasively obtained PECs.

5. Conclusion

In summary, we have utilized PEC enumeration to demonstrate the ability to discriminate benign from MPEs in patients with NSCLC. We demonstrate the feasibility to detect PD-L1 expression on PECs from MPE. Such immunophenotyping could potentially be utilized to determine candidacy for immunotherapy or assess markers of acquired resistance. The enumeration of PECs was independently associated with poor overall survival. Further studies are needed to validate the detection of PECs in MPE and explore their use as a diagnostic and prognostic marker.

Conflicts of interest disclosure

In the interest of full transparency, the CellSearch® platform was provided to our laboratory through an agreement with Menarini Silicon Biosystems. Aside from that agreement, and on behalf of my co-authors and myself we would like to disclose that there are no potential conflicts of interest and all authors have read and approved the manuscript.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.lungcan.2018.11.020.

References

[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018, CA Cancer J. Clin. 68 (2018) 7–30.

[2] E. Massarelli, A. Onn, E.M. Marom, et al., Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion, Clin. Lung Cancer 15 (2014) 379–386.

[3] F. Rodriguez-Panadero, F. Borderas Naranjo, J. Lopez Mejias, Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series, Eur. Respir. J. 2 (1989) 366–369.

[4] J.M. Thomas, A.I. Musani, Malignant pleural effusions: a review, Clin. Chest Med. 34 (2013) 459–471.

[5] K.V. Nance, R.W. Shermer, F.B. Askin, Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination, Mod. Pathol. 4 (1991) 320–324.

[6] L.W. Garcia, B.S. Ducatman, H.H. Wang, The value of multiple fluid specimens in the cytological diagnosis of malignancy, Mod. Pathol. 7 (1994) 665–668.

[7] D.T. Arnold, D. De Fonseka, S. Perry, et al., Investigating unilateral pleural effusions: the role of cytology, Eur. Respir. J. (2018).

[8] C. Hooper, Y.C. Lee, N. Maskell, Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010, Thorax 65 (Suppl. 2) (2010) ii4–17.

[9] C.W. Bedrossian, Diagnostic problems in serous effusions, Diagn. Cytopathol. 19 (1998) 131–137.

[10] K.B. Sriram, V. Relan, B.E. Clarke, et al., Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas, BMC Cancer 12 (428) (2012).

[11] H.T. Tse, D.R. Gossett, Y.S. Moon, et al., Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping, Sci. Transl. Med. 5 (2013) 212ra163.

[12] J.H. Lee, J.H. Chang, Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer, Chest 128 (2005) 2298–2303.

[13] W.J. Allard, J. Matera, M.C. Miller, et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases, Clin. Cancer Res. 10 (2004) 6897–6904.

[14] M. Cristofanilli, G.T. Budd, M.J. Ellis, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N. Engl. J. Med. 351 (2004) 781–791.

[15] M. Cristofanilli, K.R. Broglio, V. Guarneri, et al., Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden, Clin. Breast Cancer 7

(2007) 471–479.

[16] D.F. Hayes, M. Cristofanilli, G.T. Budd, et al., Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival, Clin. Cancer Res. 12 (2006) 4218–4224.

[17] G.T. Budd, M. Cristofanilli, M.J. Ellis, et al., Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer, Clin. Cancer Res. 12 (2006) 6403–6409.

[18] D.R. Shaffer, M.A. Leversha, D.C. Danila, et al., Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer, Clin. Cancer Res. 13 (2007) 2023–2029.

[19] S.J. Cohen, C.J. Punt, N. Iannotti, et al., Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer, J. Clin. Oncol. 26 (2008) 3213–3221.

[20] D.C. Danila, G. Heller, G.A. Gignac, et al., Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer, Clin. Cancer Res. 13 (2007) 7053–7058.

[21] J.M. Hou, M.G. Krebs, L. Lancashire, et al., Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer, J. Clin. Oncol. 30 (2012) 525–532.

[22] S.H. Au, J. Edd, A.E. Stoddard, et al., Microfluidic isolation of circulating tumor cell clusters by size and asymmetry, Sci. Rep. 7 (2433) (2017).

[23] R. Maddipati, B.Z. Stanger, Pancreatic Cancer metastases harbor evidence of polyclonality, Cancer Discov. 5 (2015) 1086–1097.

[24] K.J. Cheung, V. Padmanaban, V. Silvestri, et al., Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) E854–63.

[25] N. Aceto, A. Bardia, D.T. Miyamoto, et al., Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis, Cell 158 (2014) 1110–1122.

[26] S.H. Au, B.D. Storey, J.C. Moore, et al., Clusters of circulating tumor cells traverse capillary-sized vessels, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 4947–4952.

[27] M. Mascalchi, M. Falchini, C. Maddau, et al., Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC, J. Cancer Res. Clin. Oncol. 142 (2016) 195–200.

[28] D.E. Schwed Lustgarten, J. Thompson, G. Yu, et al., Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions, Ann. Am. Thorac. Soc. 10 (2013) 582–589.

[29] J.S. de Bono, C.J. Logothetis, A. Molina, et al., Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med. 364 (2011) 1995–2005.

[30] Y. Liu, Q. Liu, T. Wang, et al., Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker, BMC Cancer 13 (2013) 202.

[31] E.A. Punnoose, S. Atwal, W. Liu, et al., Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib, Clin. Cancer Res. 18 (2012) 2391–2401.

[32] S.T. Ligthart, F.C. Bidard, C. Decraene, et al., Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer, Ann. Oncol. 24 (2013) 1231–1238.

[33] C. Nicolazzo, C. Raimondi, M. Mancini, et al., Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab, Sci. Rep. 6 (2016) 31726.

[34] M. Reck, D. Rodriguez-Abreu, A.G. Robinson, et al., Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-Cell lung Cancer, N. Engl. J. Med. 375 (2016) 1823–1833.

[35] R.S. Herbst, P. Baas, D.W. Kim, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet 387 (2016) 1540–1550.

[36] G. Cyriac, L. Gandhi, Emerging biomarkers for immune checkpoint inhibition in lung cancer, Semin. Cancer Biol. 52 (2018) 269–277, https://doi.org/10.1016/j.semcancer.2018.05.006.

[37] P.A. Harris, R. Taylor, R. Thielke, et al., Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support, J. Biomed. Inform. 42 (2009) 377–381.

[38] C.J. Langer, B. Besse, A. Gualberto, et al., The evolving role of histology in the management of advanced non-small-cell lung cancer, J. Clin. Oncol. 28 (2010) 5311–5320.

[39] H. Shigematsu, L. Lin, T. Takahashi, et al., Clinical and biological features

[40] associated with epidermal growth factor receptor gene mutations in lung cancers, J. Natl. Cancer Inst. 97 (2005) 339–346.

[40] T.J. Lynch, D.W. Bell, R. Sordella, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med. 350 (2004) 2129–2139.

[41] M.F. Tsai, T.H. Chang, S.G. Wu, et al., EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway, Sci. Rep. 5 (13574) (2015).

[42] S.G. Wu, C.H. Gow, C.J. Yu, et al., Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma, Eur. Respir. J. 32 (2008) 924–930.

[43] J. Soh, S. Toyooka, K. Aoe, et al., Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer, Int. J. Cancer 119 (2006) 2353–2358.

[44] A.J. Smits, J.A. Kummer, J.W. Hinrichs, et al., EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma, Cell. Oncol. (Dordr) 35 (2012) 189–196.

[45] J.M. Porcel, A. Gasol, S. Bielsa, et al., Clinical features and survival of lung cancer patients with pleural effusions, Respirology 20 (2015) 654–659.

[46] M.E. Roberts, E. Neville, R.G. Berrisford, et al., Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010, Thorax 65 (Suppl. 2) (2010) ii32–40.

[47] P. Goldstraw, K. Chansky, J. Crowley, et al., The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J. Thorac. Oncol. 11 (2016) 39–51.

[48] H.A. Saleh, M. El-Fakharany, H. Makki, et al., Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis, Diagn. Cytopathol. 37 (2009) 324–332.

[49] B. Davidson, S. Nielsen, J. Christensen, et al., The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells, Am. J. Surg. Pathol. 25 (2001) 1405–1412.

[50] B.Y. Jiang, Y.S. Li, W.B. Guo, et al., Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells, Clin. Cancer Res. 23 (2017) 5480–5488.

[51] E.B. Garon, N.A. Rizvi, R. Hui, et al., Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med. 372 (2015) 2018–2028.

[52] S. Burugu, A.R. Dancsok, T.O. Nielsen, Emerging targets in cancer immunotherapy, Semin. Cancer Biol. (2017).

[53] C. Paoletti, M.C. Muniz, D.G. Thomas, et al., Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer, Clin. Cancer Res. 21 (2015) 2487–2498.

[54] T.S. Mok, Y.L. Wu, S. Thongprasert, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med. 361 (2009) 947–957.

[55] M. Maemondo, A. Inoue, K. Kobayashi, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362 (2010) 2380–2388.

[56] M.G. Kris, B.E. Johnson, L.D. Berry, et al., Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA 311 (2014) 1998–2006.

[57] J.J. Lin, S. Cardarella, C.A. Lydon, et al., Five-year survival in EGFR-Mutant metastatic lung adenocarcinoma treated with EGFR-TKIs, J. Thorac. Oncol. 11 (2016) 556–565.

[58] Z. Mu, C. Wang, Z. Ye, et al., Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer, Breast Cancer Res. Treat. 154 (2015) 563–571.

[59] C. Patriarca, R.M. Macchi, A.K. Marschner, et al., Epithelial cell adhesion molecule expression (CD326) in cancer: a short review, Cancer Treat. Rev. 38 (2012) 68–75.

[60] I. Kubisch, A. de Albuquerque, D. Schuppan, et al., Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas, Oncology 89 (2015) 294–303.

[61] C.J. Piyathilake, A.R. Frost, H. Weiss, et al., The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung, Hum. Pathol. 31 (2000) 482–487.

[62] P. Went, M. Vasei, L. Bubendorf, et al., Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers, Br. J. Cancer 94 (2006) 128–135.